Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00688610
NCT00688610CompletedPhase 2

Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter

Hannover Medical School1 site in 1 country571 target enrollmentStarted: November 1, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
571
Locations
1
Primary Endpoint
days with significant impairment due to acute respiratory tract infection
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Antibiotics in patients with acute respiratory tract infections in primary care in consideration of procalcitonin as additive parameter.

The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •18 years or older
  • •Informed consent
  • •Respiratory tract infection based on the clinical judgement of the primary care physician

Exclusion Criteria

  • •Antibiotic pretreatment in previous 14 days
  • •Portal hypertension
  • •Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks
  • •Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)
  • •Peritoneal dialysis
  • •Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid
  • •Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis

Outcomes

Primary Outcomes

days with significant impairment due to acute respiratory tract infection

Time Frame: 14 to 28 days after infection

Secondary Outcomes

  • number of antibiotic prescriptions(28 days)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
ABC-trial.
NL-OMON2544560
Not yet recruiting
Not Applicable
A Cluster Randomized Controlled Trial to Compare the Rate of Antibiotic InfusionBacterial InfectionsAcute Upper Respiratory Tract Infection
NCT06620341Second Affiliated Hospital, School of Medicine, Zhejiang University11,900
Active, not recruiting
Phase 1
The ATHENIAN Study: A clinical trial investigating the efficacy and safety of discontinuing antibiotic therapy in adult patients infected with respiratory virusesPatients with viral respiratory tract infection (influenza virus, parainfluenza virus, respiratory syncytial virus or human metapneumovirus)
EUCTR2021-004248-11-NOAkershus University Hospital400
Active, not recruiting
Phase 1
Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult patients infected with respiratory virusesViral respiratory tract infection
CTIS2023-509286-20-00Akershus University Hospital400
Not yet recruiting
Not Applicable
Reducing Antibiotic Prescribing in Family PracticeAcute Respiratory Tract Infection
NCT03674775Seattle Children's Hospital180